| Document |
Document Title |
|
WO/2024/059203A1 |
A ligand L capable of forming a coordinated complex with at least one metal atom, the ligand having a general formula: N(R1R2)-C(R3R4)-C(R5R6)-N(R7)-CH2-C(CR8R9R10)=O. The disclosure describes use of L to form liganded metallic complexes...
|
|
WO/2024/050715A1 |
Provided in the present application are amide compounds having amino groups on both ends, having general formula (I), in which A and B are independently selected from substituted or unsubstituted C1-C18 alkylene groups, C2-C18 alkenylene...
|
|
WO/2024/034767A1 |
The present invention relates to a method for producing a chiral nitroso derivative using an organic chiral catalyst compound based on (R,R)-1,2-diphenylethylenediamine (DPEN), and the like. According to the production method, a chiral n...
|
|
WO/2023/064363A9 |
The present disclosure relates to novel salts and salt forms of (2R)-2-(2-chlorophenyl)-2- (methylamino)cyclohexan-1-one (R-ketamine) and to processes for their preparation. The disclosure is also directed to pharmaceutical compositions ...
|
|
WO/2024/028876A1 |
The invention provides aminochalcone -diacetylene compound of Formula 1A: wherein R1 and R2 are independently selected from H and C1-C3 alkyl, A denotes a linkage connecting the chalcone and diacetylene units, m and n are independently i...
|
|
WO/2024/000920A1 |
Disclosed in the present invention is a method for preparing a β-trifluoromethylenamine compound on the basis of organic dye catalysis. The present invention belongs to the technical fields of the synthesis of medicines, pesticide produ...
|
|
WO/2023/237753A1 |
The present disclosure relates to crystalline forms of norketamine, in particular norketamine hydrochloride, processes for the preparation and uses thereof.
|
|
WO/2023/235548A1 |
Squaramide-based cannabinoid 1 receptor (CB1R) allosteric modulators are described. Exemplary analogs may provide improved potencies and pharmacokinetic properties. Methods of using the analogs to treat diseases mediated by CB1R, such as...
|
|
WO/2023/165522A1 |
The present application relates to a benzophenone derivative, and a preparation method therefor and the use thereof. The benzophenone derivative has a structure as represented by formula (1). The benzophenone derivative can be used as an...
|
|
WO/2023/165575A1 |
The present invention relates to a new aminoketone compound, and a preparation method therefor and the use thereof. Specifically, the compound of the present invention has a structure as shown in formula (I), wherein the definition of ea...
|
|
WO/2023/151157A1 |
A chemical intermediate and a preparation method, belonging to the technical field of dye intermediate synthesis. The chemical intermediate provides a new way for preparing anthraquinone dyes and dye intermediates. The preparation method...
|
|
WO/2023/149559A1 |
[Problem] The present invention provides a catalyst for hydrogenation reactions, the catalyst having excellent catalyst durability and being capable of selectively hydrogenating only some functional groups and/or unsaturated bonds of an ...
|
|
WO/2023/125001A1 |
A cyclic 1,3-diketonediimine compound, and a synthesis method therefor and the use thereof. The cyclic 1,3-diketonediimine compound has a structure as shown in the following general formulas I, II or III, wherein R1-R8 are each independe...
|
|
WO/2023/116940A1 |
The present invention relates to a simple method for modifying a precursor of a β-ketoimine ligand, comprising: reacting an LPhH2 solution with a lithium compound; then adding halogenated hydrocarbon for a C-C bond coupling reaction; an...
|
|
WO/2023/080198A1 |
An anthraquinone compound represented by formula (1) (In the formula, R1 and R4 represent a hydrogen atom, a C1-12 alkyl group, a C1-12 alkoxy group, a halogen atom, -CО2R9, -ОCОR9, -CОR9, a cyano group, or a trifluoromethyl group. R...
|
|
WO/2023/063408A1 |
An anthraquinone compound represented by formula (1): (where R1 and R4 represent -H, a C1-C12 alkyl group, a C1-C12 alkoxy group, a halogen atom, -CO2R9, -OCOR9, -COR9, a cyano group, or -CF3, R2, R3, R5 and R6 represent -H, a C1-C4 alky...
|
|
WO/2023/059640A1 |
The present disclosure provides compounds, compositions containing such compounds, and methods of designing, developing, producing and preparing compounds represented by general Formula (I), including pharmaceutically acceptable salts th...
|
|
WO/2023/057545A1 |
A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in a method of therapy, wherein: R1 is selected from: (i) phenyl, optionally substituted by R1a and R1b; (ii) pyridyl; and (iii) naphthyl, optionally subst...
|
|
WO/2023/044343A1 |
The present disclosure details various lipids, compositions, and/or methods of optimized systems and delivery vehicles for the delivery of nucleic acid sequences, polypeptides or peptides for use in vaccinating against infectious agents.
|
|
WO/2023/024532A1 |
Disclosed in the present invention is a one-step method for preparing a C-N coupling product using nitroaromatic hydrocarbon and alkyl or phenylboronic acid. The method comprises: adding nitroaromatic hydrocarbon, alkyl or phenylboronic ...
|
|
WO/2023/018990A2 |
New lipids are provided that are useful for delivering macromolecules, such as nucleic acids, into eukaryotic cells and tissue. The lipids can be used alone, in combination with other lipids and/or in combination with other transfection ...
|
|
WO/2023/013973A1 |
The present invention relates to a novel method for preparing a rucaparib, enabling excellent synthesis yield and reproducibility to be achieved. More particularly, the present invention relates to: a novel preparation method for synthes...
|
|
WO/2023/013974A1 |
The present invention relates to a method for producing novel rucaparib which can achieve an excellent synthesis yield and reproducibility. More particularly, the present invention relates to: a novel production method for synthesizing r...
|
|
WO/2023/285883A1 |
Disclosed herein are embodiments of a bi-functionalized dicyclopentadiene monomer and polymer embodiments formed therefrom. The monomer embodiments exhibit tunability and can be used to form thermally stable homopolymers, copolymers, and...
|
|
WO/2022/272174A1 |
Provided herein are arylcyclohexylamines and their use in the treatment of psychiatric disorders.
|
|
WO/2022/261030A1 |
The present disclosure relates to compounds and methods of modulating target nucleic acids that contain single nucleotide polymorphisms such as KRAS codon 12 mutations. Compounds disclosed herein can preferentially bind a sequence of nuc...
|
|
WO/2022/246572A1 |
The present application relates to combination compositions comprising one or more hallucinogens, or a pharmaceutically acceptable salt, prodrug and/or solvate thereof, and one or more fatty acids, or a pharmaceutically acceptable salt, ...
|
|
WO/2022/225868A1 |
Disclosed are compounds comprising ketamine (2-(2-chlorophenyl)-2-(methylamino)- cyclohexanone) chemically conjugated to one or more oxoacids, amino acids, polyethylene glycols (PEG or PEO), peptides, phosphates, and/or vitamin compounds...
|
|
WO/2022/221942A1 |
Implantable product(s) and methods for predetermined release of one or more active pharmaceutical ingredients (APIs). More specifically, implantable, subcutaneous product(s) and methods for treating depression and other mental and/or moo...
|
|
WO/2022/208144A1 |
A process for preparing a crystalline form of a 2-(2-chlorophenyl)-2-(methylamino) cyclohexanone hydrochloride, comprising addition of a 1-[-(2-chlorophenyl) (methylamine) methyl] cyclopentanol hydrochloride to a first organic solvent to...
|
|
WO/2022/193601A1 |
The present invention relates to an aggregation-induced luminescent compound, and a supramolecular polymerized fluorescent nano-material and a preparation method therefor. The preparation method for the supramolecular polymerized fluores...
|
|
WO/2022/153962A1 |
The problem to be solved by the present invention is to provide: a compound useful as a hole transport material for photoelectric conversion elements whereby electric current can be efficiently taken out; and a photoelectric conversion e...
|
|
WO/2022/092260A1 |
The present invention addresses the problem of providing a cross-coupling reaction method that can use a wide variety of compounds as starting materials, that can substantially not use organic solvent, and that can rapidly provide reacti...
|
|
WO/2022/089598A1 |
A flavonoid glycoside and organic amine neuroagonist double salt compound, a preparation method therefor, and an application thereof, a pharmaceutical composition containing a therapeutically effective amount of the double salt compound ...
|
|
WO/2022/076507A1 |
The present disclosure relates to compounds that are capable of inhibiting PRMT8 and/or upregulating SirTl. The disclosure further relates to methods of treating neurodegenerative diseases and disorders (e.g., Alzheimer's disease).
|
|
WO/2022/061920A1 |
A method for preparing 3',5'-dichloro-2,2,2-trifluoroacetophenone. The method comprises subjecting 3'-chloro-2,2,2-trifluoroacetophenone as a raw material to four steps, i.e. nitrification, reduction, chlorination and deamination, so as ...
|
|
WO/2022/061914A1 |
The present application relates to the technical field of chemical pharmacy, and in particular, to a method for preparing 3,5-dihalotrifluoroacetophenone and a derivative thereof. 3-halogen-4-nitrotrifluoroacetophenone is used as a raw m...
|
|
WO/2022/058916A1 |
The present invention disclosed a process for the synthesis of compound of formula (Z) or a salt thereof, wherein, R, R1, R2, R3 and R10 are as defined in the detailed description. The process further comprises the synthesis of an anthra...
|
|
WO/2022/014344A1 |
Provided is a thin film-forming material containing a yttrium compound represented by general formula (1). (In the formula, R1 and R3 each independently represent an alkyl group having 1-6 carbon atoms or an alkoxyalkyl group having 2-...
|
|
WO/2021/255737A1 |
The present disclosure pertains to amino cyclohexanone compounds, pharmaceutical compositions containing same and methods of treating depression, pain, inflammation, and other clinical indications.
|
|
WO/2021/234697A1 |
The present invention pertains to compositions and methods for treating inflammation in a subject in need thereof using hydroxynorketamine (HNK), a salt thereof, a stereoisomer thereof, or a combination thereof.
|
|
WO/2021/233805A1 |
The present invention relates to a process for purifying 2-(4'-diethylamino-2'-hydroxybenzoyl)benzoic acid hexyl ester providing a high purity and low phthalic acid dialkyl ester content.
|
|
WO/2021/212974A1 |
A racemic and chiral 3-(2,3-butadienyl)oxyindolinone compound, a method for preparing the compound using a palladium catalyzed coupling reaction and an application thereof. According to the preparation method, 2,3-butadienyl carbonate an...
|
|
WO/2021/208951A1 |
Disclosed is a β-diketone cerium (IV) compound of formula (I). The compound has a wide absorption band, is suitable for near ultraviolet-visible region curing as a photoinitiator, and has a high sensitiveness, while also having the adva...
|
|
WO/2021/071033A9 |
The present invention relates to a method for preparing diethylamino hydroxybenzoyl hexyl benzoate and, specifically, to: a method for preparing diethylamino hydroxybenzoyl hexyl benzoate, which has a simple preparation process and can b...
|
|
WO/2021/189528A1 |
Disclosed are a thermally activated delayed fluorescent material and a synthesis method therefor, and an electroluminescent device. The thermally activated delayed fluorescent material is a target compound synthesized by reaction of an e...
|
|
WO/2021/175901A1 |
The present invention relates to the technical field of pharmaceutical synthesis and development of drugs, and to a process for preparing cyclic 2-amino-1-one derivatives and to the reaction products and intermediates obtainable by this ...
|
|
WO/2021/142062A1 |
Described herein are pharmaceutical compositions comprising one or more fumarate esters and methods for treating multiple sclerosis subjects with the compositions where the incidence of gastrointestinal side effects is reduced compared t...
|
|
WO/2021/134820A1 |
Disclosed are a new organic electroluminescent compound and an organic electroluminescent device. The structural formula of the organic electroluminescent compound is as shown below: (I), wherein L1 and L2 are phenylene, and L1 and L2 ma...
|
|
WO/2021/138443A1 |
Methods and compositions for modifying the course and severity of neuropsychiatric disorders. The method includes administering a composition to a subject suffering from a neuropsychiatric disorder, wherein the composition includes a sub...
|
